‹ÆÑ

2020E2019E2018E2017 E2016E2015E2014E2013E2012E2010

ƒJƒeƒSƒŠ[•Ê

2011

(˜_•¶)

Ichihara H, Nakamae H, Hirose A, Nakane T, Koh H, Hayashi Y, Nishimoto M, Nakamae M, Yoshida M, Bingo M, Okamura H, Aimoto M, Manabe M, Hagihara K, Terada Y, Nakao Y, Hino M.
Immunoglobulin prophylaxis against cytomegalovirus infection in patients at high risk of infection following allogeneic hematopoietic cell transplantation.

Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M
@Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.

Nakane T, Nakamae H, Koh H, Nakamae M, Hayashi Y, Nishimoto M, Yoshimura T, Inoue E, Inoue A, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Hino M
@Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.

^çéŽõ(‘åãŽs—§‘åŠw), —ш×m, ”‹Œ´Œ‰’Ê, ™ŽR—T”V, ˆÀ“¡Œ’Ž¡, ‹àŽç—Ç, “ú–ì‰ë”V
@PTHrP‚Ì㸂𔺂¤‚CaŒŒÇ‚ª”F‚ß‚ç‚êR-CHOP—Ö@‚ª—LŒø‚Å‚ ‚Á‚½B×–E«ˆ««ƒŠƒ“ƒpŽî

Šà‚Ɖ»Šw—Ö@ 2011 38i11j:1881-1884

‘Š–{Ž÷(‘åãŽs—§‘åŠw), ŽRªF‹v, ˆê‹[, XŽm, ‘Š–{—–, ˆäãŒb—¢, NG’j, ’†ªF•F, •‰ªNM, ’†‘O”ü‰À, ¬â‚³‚¨‚è, Ž›“c–FŽ÷, ’†‘O”Ž‹v, ‚‹N—Ç, ’†”ö—²•¶, ‘åàV­•F, Žá‹·Œ¤ˆê, Αº‰hŽ¡, ˆî—t‰ëÍ, “ú–ì‰ë”V
@“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚É–Œ«tÇ‚É‚æ‚éƒlƒtƒ[ƒ[ÇŒóŒQ‚ð”­Ç‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a

—Õ°ŒŒ‰t 2011 52i7j:556-562
•‰ªNMi‘åã•{϶‰ï’†’Õa‰@jAˆî—tWŽqA“¡’J—m‘¾˜YA¬â‚³‚¨‚èAŽR‘º—º‰îAŽRè‰plA‰ª‘ºŒõ‰pA‘¾“cŒ’‰î
@FDG-PET/CT‚ªf’f‚É—LŒø‚Å‚ ‚èAŽq‹{“à–Œ¶ŒŸ‚Åf’f‚Å‚«‚½ŒŒŠÇ“à‘å×–EŒ^B×–EƒŠƒ“ƒpŽî.i•\Ž†‚ÌŽÊ^‚É‚àÌ—p‚³‚ê‚Ü‚µ‚½j
—Õ°ŒŒ‰t 2011 52i11j:1777-1781
Manabe Mi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jAYoshii YAMukai SASakamoto EAKanashima HAInoue TATeshima H
@A rare t(9;22;16)(q34;q11;q24) translocation in chronic myeloid leukemia for which imatinib mesylate was effective: a case report
ŠÔ•” Œ«Š°i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‘O“c ˆêÎ,  ˆäã Œ’, Žè“‡ ”Ž•¶
@pŒã8”N‚ðŒo‰ß‚µ, œ‘ŠàŽîÇ‚ð ’悵‚ÄÄ”­‚µ‚½ˆÝŠà (ˆóŠÂ×–EŠà)..
—Õ°ŒŒ‰t 2011 52i5j:431
Manabe Mi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jAYoshii YAMukai SASakamoto EAKanashima HAOhta KAInoue T, Teshima H
@Transient efficacy of cord blood transplantation in acute myeloid leukemia with t(16;21)(p11;q22)
’†”ö—²•¶i‘åãŽs—§‘åŠwjA‹g“c“TŽqA’†ªF•FAŽ›“c–FŽ÷A’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
@–òÜ«–³è÷—±‹…Ç‚ð”­Ç‚µ‚½–«œ‘«”’ŒŒ•a.
Nakao Ti‘åãŽs—§‘åŠwj, Yamane T, Katagami T, Shiota M, Izumi Y, Samori T, Hino M, Iwao H
@Severe prekallikrein deficiency due to a homozygous Trp499Stop nonsense mutation.
‹v‘ºŠx‰›i¶’·‰ï•{’†•a‰@jAÂŽR‘×FAŽsŒ´O‹`AN@Žj˜NAêm’JˆÀ’ÃŽqA‘ì‚ЂƂÝAs‰ªŒc‰îA–؉º@’eA’†ì¹ŽqAŽRú±‘¥s.
@ˆâ“`Žq‘gŠ·‚¦Œ^ƒqƒgƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“»Ü‚ƃKƒxƒLƒT[ƒgƒƒVƒ‹Ž_‰–‚Ì•¹—p“Š—^‚ª—LŒø‚Å‚ ‚Á‚½ŽY‰ÈDIC‚Ì3Ç—á.
—Õ°ŒŒ‰t 2011;52(2): 68-72
Shibata M, Ezoe S, Oritani K, Matsui K, Tokunaga M, Fujita N, Saito Y, Takahashi T, Hino M, Matsumura I, Kanakura Y.
@Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylation.
Nakamae H, Storer B, Sandmaier BM, Maloney DG, Davis C, Corey L, Storb R, Boeckh M.
@Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact ofrecipient/donor factors, transplant conditions and myelotoxic drugs.
Kantarjian HM, Hochhaus A, Saglio G, Souza CD, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.
@Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Iida M, Fukuda T, Ikegame K, Yoshihara S, Ogawa H, Taniguchi S, Takami A, Abe Y, Hino M, Etou T, Ueda Y, Yujiri T, Matsui T, Okamura A, Tanaka J, Atsuta Y, Kodera Y, Suzuki R.
@Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.
Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda Y, Matsuda A, Amagasaki T, Yanada M.
@Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Koh H, Hayashi T, Sato KK, Harita N, Maeda I, Nakamura Y, Endo G, Kambe H, Fukuda K
@Blood pressure components and risk for chronic kidney disease in middle-aged Japanese men: The Kansai Healthcare Study.
Koh H, Hayashi T, Sato KK, Harita N, Maeda I, Nishizawa Y, Endo G, Fujimoto WY, Boyko EJ, Hikita Y
@Visceral adiposity, not abdominal subcutaneous fat area, is associated with high blood pressure in Japanese men: the Ohtori study.
Chihara T, Wada N, Ikeda J, Fujita S, Hori Y, Ogawa H, Sugiyama H, Nomura S, Matsumura I, Hino M, Kanakura Y, Morii E, Aozasa K.i‘åナƒ“ƒpŽîŒ¤‹†‰ïj
@Frequency of intravascular large B-cell lymphoma in Japan: study of the Osaka Lymphoma Study Group.
Zaki MA, Wada N, Kohara M, Ikeda J, Hori Y, Fujita S, Ogawa H, Sugiyama H, Hino M, Kanakura Y, Morii E, Aozasa K.i‘åナƒ“ƒpŽîŒ¤‹†‰ïj
@Presence of B-cell clones in T-cell lymphoma.
Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N.
@Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K,
Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M,
Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno
R.
@A randomized comparison of four courses of standard-dose multiagent chemotherapy

versus three courses of high-dose cytarabine alone in post-remission therapy for acute
myeloid leukemia in adults: the JALSG AML201 study.
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; the TARGET investigators.
@Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K, Togami K, Nishiwaki K, Ueda Y, Kawano F, Kasai M, Nagafuji K, Hagihara M, Hatanaka K, Taniwaki M, Maeda Y, Shirafuji N, Mori T, Utsunomiya A, Eto T, Nakagawa H, Murata M, Uchida T, Iida H, Yakushiji K, Yamashita T, Wake A, Takahashi S, Takaue Y, Taniguchi S.
@Feasibility of Reduced-intensity Cord Blood Transplantation as Salvage Therapy for Graft Failure: Results of a Nationwide Survey of 80 Adult Patients.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R.
@Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study.

Wada N, Ikeda J, Hori Y, Fujita S, Ogawa H, Soma T, Sugiyama H, Fukuhara S, Kanamaru A, Hino M, Kanakura Y, Morii E, Aozasa K.i‘åナƒ“ƒpŽîŒ¤‹†‰ïj
@Epstein-barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries.
“ú–ì‰ë”V
@“à‘Ÿ”dŽí«…“—‘Ñóáv]ƒEƒCƒ‹ƒXŠ´õÇmf—ẪRƒcn
–L“ˆ’“¿i•Òj Ç—á‚ƃGƒrƒfƒ“ƒX‚ÉŠw‚Ô‘¢ŒŒ×–EˆÚA‚ÆŠ´õÇAˆã–òƒWƒƒ[ƒiƒ‹ŽÐ@2011;36-39
“ú–ì‰ë”V
@–«‰ŠÇ‚ÉŠÖ‚·‚é•nŒŒ‚É‚¨‚¯‚éƒrƒ^ƒ~ƒ“‚cŒ‡–R
ŒŒ‰t“à‰È 2011;63(6):708-713

 

(Šw‰ï)

‘æ196‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‹ž“sƒeƒ‹ƒTA‹ž“sA12ŒŽ17“ú
‘Ζƒáƒ‚É‚Ä”­Ç‚µƒ‰ƒ“ƒ_ƒ€”畆¶ŒŸ‚É‚Äf’f‚µ“¾‚½ŒŒŠÇ“à‘å×–EŒ^BƒŠƒ“ƒpŽî‚Ì‚P—á.
•S£@‘åiJR‘åã“S“¹•a‰@jA›–ìˆÀŠìA‚@‹N—ÇA˜a“cŸ–çA–Ø‘ºÊA´–ì@ˆ¤AŽR–{F“¿AŠâ–{ˆêG
H. influenzae‚É‚æ‚é”x‰Š‚©‚çSƒ^ƒ“ƒ|ƒi[ƒf‚𗈂µ‚½ˆ««ƒŠƒ“ƒpŽî‚Ì‚P—á.
Œüˆä@Œåi‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA‹à“‡@LA’†”ö—²•¶AŽRªF‹vA‹gˆä—R”üAŠÔ•”Œ«Š°Aâ–{Œb—˜“ÞAŽè“‡”Ž•¶

 

53th American Society of Hematology
San-DiegoADec 10-13
2000
Risk Factors Affecting Cardiac Left Ventricular Systolic and Diastolic Function and Hypertrophy in the Chronic Phase Post-Allogeneic Hematopietic Cell Transplantation

Nishimoto M, Nakamae H, Nakane T, Koh H, Hayashi Y, Nakamae M, Yoshida M, Bingo M, Okamura H, Aimoto M, Manabe M, Yoshimura T, Inaba A, Nanno S, Hirose A, Hagihara K, Nakao Y, Terada Y, Hino M

3764
Immunoprofile of Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib

Hayashi Y, Nakamae H, Katayama T, Nakane T, Koh H, Nishimoto M, Nakamae M, Yoshida M, Bingo M, Okamura H, Aimoto M, Manabe M, Yoshimura T, Inaba A, Nanno S, Hagihara K, Nakao Y, Terada Y, Hino M

3071[‹¤“¯Œ¤‹†]
Double-Unit Cord Blood Transplantation for Hematological Malignancies in Japan: Multicenter Phase II Study (C-SHOT 0507)

Wake A, Kai SR, Okada M, Kurata M, Atsuta Y, Ishikawa J, Hino M, Aotsuka N , Kasai M, Misawa M, Taniguchi S, Kato S

452[‹¤“¯Œ¤‹†](oral)
Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up

Saglio G, LeCoutre PD, Pasquini R, Jootar S, Nakamae H, Flinn IW, Hochhaus A, Hughes TP, Larson RA, Hoenekopp A, Gallagher NJ, Yu R, Blakesley RE, Kim DW, Kantarjian HM

1935[‹¤“¯Œ¤‹†]
Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation (RIST) for Patients Aged 50-70 Years with Acute Lymphoblastic Leukemia (ALL) in Remission: A Study From the ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

Kanamori H, Kako S, Kato H, Nishiwaki S, Furukawa T, Saito M, Taniguchi S, Nakamae H, Yujiri T, Naganuma-Inoue T, Morishima Y, Suzuki R, Sakamaki H, Tanaka  J

 

‘æ96‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
ƒeƒCƒWƒ“ƒz[ƒ‹A‘åãA11ŒŽ12“ú
ä`‘ÑŒŒˆÚAŒã‚ÉSƒ^ƒ“ƒ|ƒi[ƒf‚ð”­Ç‚µS”X‰t‚©‚çHHV6 DNA‚ªŒŸo‚³‚ꂽˆê—á.
‹g“c‘SGAN@G’jA‰ª‘º_ŽjA”õŒã^“oA¼–{ŒõFA—Ñ@—ÇŽ÷AŠÔ•”Œ«Š°A ’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”V
ƒEƒTƒMATG“Š—^‚É‚Ä‹}Œƒ‚ÈŠÌy‘f‚Ì㸂ð”F‚ß‚½Ä¶•s—Ç«•nŒŒ.
•S£@‘åiJR‘åã“S“¹•a‰@jA›–ìˆÀŠìA‚@‹N—ÇA˜a“cŸ–ç
‘½”­«œ‘Žî‚ɑ΂·‚éƒ{ƒ‹ƒeƒ]ƒ~ƒu‚Ìdose intensity‚Æ—\Œã‚ɂ‚¢‚Ä‚ÌŒŸ“¢.
‰ª–{Gˆê˜Yi¶’·‰ï•{’†•a‰@jAN@Žj˜NAÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽqA‘¾“c’‰MAŒÃì‰À‰›

 

‘æ49‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï
–¼ŒÃ‰®‘Û‰ï‹cêA–¼ŒÃ‰®A10ŒŽ27“úE29“ú
5”ÔõF‘Ì’·˜rŒ‡Ž¸‚𔺂¤œ‘ˆÙŒ`¬ÇŒóŒQ‚ɑ΂·‚郌ƒiƒŠƒhƒ~ƒh‚ÌŽg—pŒoŒ±.
êm’JˆÀ’ÃŽqAN@Žj˜NA‰ª–{Gˆê˜YAÂŽR‘×FA‹v‘ºŠx‰›A‘¾“c’‰MAŒÃì‰À‰›A•S£@‘åA•½ˆä@ŠwA“¡’J—m‘¾˜YA‘¾“cŒ’‰îA“ú–ì‰ë”V
R-CHOP—Ö@‚ÅŠ®‘SŠ°‰ð‚𓾂½‘O—§‘BŒ´”­‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–EƒŠƒ“ƒpŽîÇ—á.
ŠÔ•”Œ«Š°, —Ñ—ÇŽ÷, ‹gˆä—R”ü, ŒüˆäŒå, â–{Œb—˜“Þ, ‹à“‡L, —tŽR‘ô–, ‹v•Û—E‹L, •Ÿ“‡—TŽq, ˆä㌒, Žè“‡”Ž•¶

 

‘æ73‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï
–¼ŒÃ‰®‘Û‰ï‹cêA–¼ŒÃ‰®A10ŒŽ14“úE16“ú

OS-1-52
Experience of lenalidomide therapy for multiple myeloma in a community setting in Osaka.
Takaoka Yi‘åã•{϶‰ï’†’Õa‰@jAOhta KAYamamura RAKosaka SAFujitani YAInaba AAMugitani AAKumura TAAoyama YAIchihara HAKoh SAYamane TAKanashima HASakamoto EAHashimura MAYoshii YAHirai MAMomose DAWada KAKoh KRASugano YAOkamoto SATeshima HANakao TAHino M

OS-1-111
Serum cytokine profiles in hemophagocytic syndrome after allogeneic hematopoietic cell transplant.
Koh HAKoh KRANakane TASakamoto EAKatayama TANakamae MATerada YANakamae HAYamane TAHino M

PS-1-104
A rare case of CD7+, CD56+ and Ph-positive early precursor B-ALL.
Yoshida MANakane TAOkamura HABingo MAAimoto MANishimoto MAHayashi YAManabe MAKoh HAHagihara KANakamae MATerada YANakamae HAHino M
OS-2-4(‹¤“¯Œ¤‹†)
The TARGET system provides more practical and general features compared with the IRIS study.
Tauchi TAKizaki MAOkamoto SAHanaka HATanimoto MAInokuchi KASaburi YAHino MAIsobe YAOshimi KADan KAOhyashiki KAIkeda Y
OS-2-6(‹¤“¯Œ¤‹†)
Dasatinib versus Imatinib in patients with newly diagnosed chronic-phase CML: Japanese subanalysis.
Ogura MANakamae HAFujisawa SAIshizawa KATaniwaki MAUtsunomiya AAMatsue KATamura KAUsuki KATanimoto MAIshida YAAkiyama HASakai RAKasai MAHino MATakeyama KASeriu TABradley-Garelik MBAZhu C
OS-2-10(‹¤“¯Œ¤‹†)
Multi-center clinical study evaluating the CMR/MMR ratio of CML-CP by high-sensitive IS-Q-PCR test.
Nishiwaki KATakahashi NAWakita HAShinohara YATakahara SASano KAMasuoka HAAotsuka NAMatsuura YAHirasawa AANakamura HAKashimura MAFukazawa MATanaka HANakagawa YAMatsue KAItoh KAHatano YAKuroki JANakayama YAIchikawa YAChubachi AANimura TAMotegi MAMugitani AANakane TANakamae HAHino MASawada KAMiyazaki Y
PS-2-147
Cold-AIHA in a case of MDS relapsed after allogeneic bone marrow transplantation.
Okamura HANakane TAYoshida MABingo MAAimoto MANishimoto MAHayashi YAManabe MAKoh HANakamae MATerada YANakamae HAHino M

PS-2-172
Primary gastric T-cell lymphoma without Human T cell Leukemia Virus Type 1: a case report.
Manabe MAYamane TAInaba AANanno SAInoue AAAimoto MAOkamura HAYoshida MABingo MANishimoto MAHayashi YAKoh HANakane TANakamae MAHagihara KATerada YANakamae HANakamura MAMuguruma KAOhsawa MAHino M

PS-2-208
Reversible posterior leukoencephalopathy following acute pancreatitis in a patient with leukemia.
Nishimoto MAKoh HAHayashi YAManabe MABingo MAYoshoda MAOkamura HAHirose AANakamae MAHagihara KANakane TATerada YANakamae HAHino M
OS-3-100
The immunoprofile of
patients with CML treated with imatinib, nilotinib or dasatinib.
Hayashi YANakamae HAKatayama TANakane TAKoh HANishimoto MANakamae MAYoshida MABingo MAOkamura HAAimoto MAManabe MAHagihara KANakao YATerada YAHino M
OS-3-157
Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders.
Koh HAHino MAOhta KAIino MAUrase FAYamaguchi MAYamanouchi JAUsui NAYoshida MATanimoto MAOhyashiki KAUrabe AATamura KAKanamaru AAMasaoka T

 

‘æ195‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
‘åã‘ی𗬃Zƒ“ƒ^[A‘åãA9ŒŽ10“ú
ä`‘ÑŒŒˆÚAŒã‚ɃgƒLƒ\ƒvƒ‰ƒYƒ}”]Ç‚ð”­Ç‚µ‚½œ‘ˆÙŒ`¬ÇŒóŒQ‚Ì‚P—á.
ˆî—tWŽqA¼–{ŒõFAN@G’jA—Ñ@—ÇŽ÷A‰ª‘º_ŽjA ’†ªF•FA’†‘O”Ž‹vA“ú–ì‰ë”VA‰º–쑾˜Y

 

‘æ9‰ñ“ú–{—Õ°Žîᇊw‰ïŠwpW‰ï
ƒpƒVƒtƒBƒR‰¡•lA‰¡•lA7ŒŽ21“úE23“ú
pŒã8”N‚ðŒo‰ß‚µ, œ‘ŠàŽîÇ‚ð’悵‚ÄÄ”­‚µ‚½ˆÝŠàÇ—á.
ŠÔ•”Œ«Š°, ‹gˆä—R”ü, ŒüˆäŒå, â–{Œb—˜“Þ, ‹à“‡L, ‘O“cˆêÎ, ‹v•Û—E‹L, •Ÿ“‡—TŽq, ˆä㌒, Žè“‡”Ž•¶

 

‘æ15‰ñ“ú–{‚ª‚ñ–ƉuŠw‰ï‘‰ï
ç—¢ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXƒZƒ“ƒ^[A‘åãA6ŒŽ30“úE7ŒŽ1“ú
‘¢ŒŒŠ²×–EˆÚAŒãŠ³ŽÒ‚ɑ΂·‚éWT1ƒƒNƒ`ƒ“–Ɖu—Ö@.
•Ûå’¼‹BA‘O“c“N¶AŽRªF‹vA“ú–ì‰ë”VAX–{‘n¢ŽqAŒ´@ˆê^A’†“cA¼“cƒKA’؈五ŽA”ö˜H—S‰îA‰ª@–F

 

‘æ95‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
“sƒzƒeƒ‹ƒjƒ…[ƒAƒ‹ƒJƒCƒbƒNA“òèA6ŒŽ18“ú
”ñŒŒ‰ŽÒŠÔ“¯Ží‘¢ŒŒŠ²×–EˆÚAŒãAŽ©—¥_ŒoáŠQ‚ð’悵‚½HHV6”]‰ŠEÒ‘‰Š‚̈ê—á.
¼–{ŒõFA’†‘O”Ž‹vA—Ñ@—ÇŽ÷AŠÔ•”Œ«Š°AN@G’jA’†ªF•FAœA£’©¶A’†‘O”ü‰ÀAŽ›“c–FŽ÷A“ú–ì‰ë”V
HBVŠÖ˜AŒŒ‹…æÃHÇŒóŒQ‚ÌŽ©‘RŠ°‰ð‚É‘±‚«ƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ÌÄ”­‚ð”F‚ß‚½‚—îŽÒ—á.
˜a“cŸ–çiJR‘åã“S“¹•a‰@jA‹g‘º‘ì˜NA›–ìˆÀŠìA‚@‹N—ÇAΓc‰p˜a
“–‰@‚É‚¨‚¯‚é”­ì«–éŠÔŒŒF‘f”AÇŠ³ŽÒ‚ɑ΂·‚éƒGƒNƒŠƒYƒ}ƒu‚ÌŽg—pŒoŒ±.
N@Žj˜Ni¶’·‰ï•{’†•a‰@jA‰ª–{Gˆê˜YAÂŽR‘×FA‹v‘ºŠx‰›A”ž’JˆÀ’ÃŽqA‘¾“c’‰MAŒÃì‰À‰›
‹³ˆçu‰‰
Aggressive lymphoma‚ÌŽ¡—Ã`Šî‘b‚©‚çÅV’mŒ©‚Ü‚Å`
.

Ž›“c–FŽ÷

 

‘æ194‰ñ“ú–{“à‰ÈŠw‰ï‹ß‹E’n•û‰ï
“Þ—ÇŒ§—§•¶‰»‰ïŠÙA“Þ—ÇA6ŒŽ11“ú
Šà«‘–Œ‰Š‚ɑ΂µ‚Äerlotinib‚ª—LŒø‚Å‚ ‚Á‚½”x‘BŠàpŒãÄ”­Ç—á.
ŠÔ•”Œ«Š°, Œõ‰ª–ÎŽ÷, ”~ì‰Á“ÞŽq, “c’†G“T, ‹g‘º¬‰›, –Ø‘º’B˜Y, •“cŒi•q, H“¡VŽO, •½“cˆêl

 

‘æ65‰ñ“ú–{Œð’ʈãŠw‰ï‘‰ï
ƒƒ‹ƒpƒ‹ƒN‹ž“sA‹ž“sA6ŒŽ4“úE5“ú
EBVÄŠˆ«‚𔺂¤ŒŒ‹…æÃHÇŒóŒQ‚É‘±‚¢‚ÄÄ”­‚ð”F‚ß‚½‚—îƒzƒWƒLƒ“ƒŠƒ“ƒpŽî.
˜a“cŸ–çiJR‘åã“S“¹•a‰@j
“Á•Êu‰‰I
“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ÌŒ»ó.
“ú–ì‰ë”V

 

‘æ97‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï
‹ž‰¤ƒvƒ‰ƒUƒzƒeƒ‹A“Œ‹žA5ŒŽ13“úE15“ú
ˆÝŒ´”­ˆ««ƒŠƒ“ƒpŽî(DLBCL)‚ÉR-CHOP—Ö@‚ðŽ{s‚µŠ°‰ð‚ª“¾‚ç‚ꂽ’¼ŒãA“¯•”ˆÊ‚É‘ŠúˆÝŠà‚ð”F‚ß‚½Ç—á.
^@çéŽõA‘å“cGˆêA…ã—zA”nêŠóˆê˜YAˆäˆêŒ›A•½’Ë‘ñ–çA”‹Œ´Œ‰’ÊAã™—TŽqA™ŽR—S”VA“ú–ì‰ë”V

 

‘æ33‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
ˆ¤•QŒ§Œ§–¯•¶‰»‰ïŠÙA¼ŽRA3ŒŽ9“úE10“ú
PS-1-100
ä`‘ÑŒŒˆÚAŒã‚ɇ•¹‚µ‚½Ž©ŒÈ–Ɖu«bó‘BŽ¾Š³‚Ì1Ç—á.
ˆäã“ÖŽii‘åãŽs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŒŒ‰tŽîᇧŒäŠwjA’†ªF•FA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ÀA—Ñ@—ÇŽ÷A¼–{ŒõFA‘Š–{Ž÷A”õŒã^“oA‹g‘º‘ì˜NA‰ª‘º_ŽjA‹g“c‘SGAŠÔ•”Œ«Š°AœA£’©¶A’†”ö‹gFAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
PS-1-015
”ñŠ°‰ðŠú‚É“¯Ží‘¢ŒŒŠ²×–EˆÚAiHCTj‚ðŽ{s‚³‚ꂽ”’ŒŒ•aŠ³ŽÒ‚Ì’·Šú¶‘¶‚ÉŠñ—^‚·‚éˆöŽq‚ÌŒŸ“¢.
N@G’ji‘åãŽs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŒŒ‰tŽîᇧŒäŠwjA’†‘O”Ž‹vA’†ªF•FA—Ñ@—ÇŽ÷A¼–{ŒõFA‘Š–{Ž÷Aˆäã“ÖŽiAŠÔ•”Œ«Š°A”õŒã^“oA‹g“c‘SGA‰ª‘º_ŽjA”~–{—R—¢AˆäãŒb—¢A‘Š–{@—–AœA£’©¶A’†‘O”ü‰ÀAŽ›“c–FŽ÷A‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
PS-2-079
“¯Žíœ‘ˆÚAŒã‚ɉ¡’f«Ò‘‰Š‚ð‡•¹‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a.
ŠÔ•”Œ«Š°i‘åãŽs—§‘åŠwŒŒ‰t“à‰ÈE‘¢ŒŒ×–EˆÚA‰ÈjA’†ªF•FAˆÉ“¡˜a”ŽA‰ª‘º_ŽjA”õŒã^“oA‹g“c‘SGAˆäã“ÖŽiA‘Š–{Ž÷A¼–{ŒõFA—Ñ@—ÇŽ÷AN@G’jA’†‘O”ü‰ÀAŽ›“c–FŽ÷A’†‘O”Ž‹vA’†”ö—²•¶A’†”ö‹gFA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
PS-1-017
“–‰È‚É‚¨‚¯‚éPh—z«ALL‚Ì“¯Ží‘¢ŒŒŠ²×–EˆÚA¬Ñ‹y‚Ñ—\ŒãˆöŽq‚ÌŒŸ“¢.
‹g‘º‘ì˜Ni‘åãŽs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŒŒ‰tŽîᇧŒäŠwjA’†ªF•FAœA£’©¶AN@G’jA’†‘O”ü‰ÀA‘Š–{@—–AˆäãŒb—¢A‘Š–{Ž÷Aˆäã“ÖŽiA¼–{ŒõFA—Ñ@—ÇŽ÷AŽ›“c–FŽ÷A’†”ö‹gFA’†‘O”Ž‹vA‚@‹N—ÇAŽRªF‹vA“ú–ì‰ë”V
ŠÅŒìPS-1-07
ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÉWII Fit‚ðŽæ‚è“ü‚ꂽŒø‰Ê‚Æ¡Œã‚̉ۑè.
X씪ç‘ãi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰È•a“jA쌳—¢A™ŽRK—éA‘ºŒû—SŽqA”g•½m”üA‹{–{’qŽqAˆîè…“ÞŽqA‰ºÎ•xKA“ì•”½Ž¡
ŠÅŒìPS-1-09
‘¢ŒŒŠ²×–EˆÚAŒãÄ”­‚µ‚½ˆ««ƒŠƒ“ƒpŽîŠ³ŽÒ‰Æ‘°‚ªÝ‘î—×{‘I‘ðŒã‚É‘ÌŒ±‚µ‚½‚±‚Æ.
’ß“c—Œbi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@ŒŒ‰t“à‰È•a“jAŽRèm”üA”g•½m”üAˆîè…“ÞŽqA‹{è‹žŽq
ŠÅŒìPS-2-03
ˆÚA•a“‚É‚¨‚¯‚銳ŽÒˆã—ÎҌ𗬉ï‚ÌŽÀ‘H•ñ.
ŽRèm”üi‘åãŽs—§‘åŠwˆãŠw•”•‘®•a‰@@ŒŒ‰t“à‰È•a“jAŽoì”ü—R‹IA‘½Ž¡”ä´ŽqA”g•½m”üA‹{–{’qŽqA’ß“c—ŒbAˆîè…“ÞŽq
‹¤“¯WS2-18-2
Œ’íƒhƒi[‚©‚ç‚Ì––½ŒŒŠ²×–E̎掞‚ÌŒŒŠÇƒAƒNƒZƒX‚Ì‚½‚߂̃fƒoƒCƒX‚ÉŠÖ‚·‚é‘S‘’²¸.
”¨’†ˆê¶i˜a‰ÌŽRŒ§—§ˆã‰È‘åŠw—AŒŒEŒŒ‰tŽ¾Š³Ž¡—Õ”jA—é–Ø—¥˜NA”M“c—RŽqA“ú–ì‰ë”VA–L“ˆ’“¿A¬Ž›—Ç®A¡‘º‰ëŠ°
‹¤“¯WS2-20-1
–¢•ª‰»‘¢ŒŒŠ²×–E‚ÌŽxŽ”\‚ðŽ‚ƒqƒgœ‘—R—ˆŠÔ—tŒnŠ²×–E‚Ì—\Šú“I•ª—£‚Æ‚»‚Ì‹@”\‰ðÍ.
¼‰ª—R˜aiŠÖ¼ˆã‰È‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰ÈŠ²×–E¶•¨ŠwjA²X–Ø@–LA‚‹´¹–çA’†’Ë—²‰îAˆäã‰ë”üA¬ìŒ[‹±A‚‹´—²KAÎì@~A“ú–ì‰ë”VA‰’“c¸º

 

–ß‚é